STOCK TITAN

Clearside Biomedical to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Clearside Biomedical (NASDAQ: CLSD) will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 9:10 a.m. ET. George Lasezkay, Pharm.D., J.D., CEO, and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer, will lead the presentation. A live and archived webcast will be accessible on the Clearside website for three months. Clearside is focused on innovative treatments for serious back of the eye diseases, utilizing its proprietary SCS Microinjector™ for targeted medication delivery.

Positive
  • None.
Negative
  • None.

ALPHARETTA, Ga., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020 at 9:10 a.m. ET.

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector™ targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.


FAQ

What is the date and time of Clearside Biomedical's presentation at the Wedbush PacGrow Healthcare Virtual Conference?

Clearside Biomedical will present on August 11, 2020, at 9:10 a.m. ET.

Who are the presenters for Clearside Biomedical at the 2020 Wedbush Conference?

The presenters are George Lasezkay, Pharm.D., J.D., and Thomas A. Ciulla, M.D., MBA.

Where can I watch the Clearside Biomedical presentation live?

The live webcast can be accessed on the Clearside website under the Investors section.

How long will the webcast of Clearside Biomedical's presentation be available?

The archived webcast will be available for three months.

What innovative technology does Clearside Biomedical utilize for treatment delivery?

Clearside Biomedical uses the SCS Microinjector™ for targeted delivery to the eye.

Clearside Biomedical, Inc.

NASDAQ:CLSD

CLSD Rankings

CLSD Latest News

CLSD Stock Data

74.75M
75.84M
7.39%
23.05%
2.61%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ALPHARETTA